Outset Medical, Inc. (NASDAQ:OM) Shares Sold by Rhumbline Advisers

Rhumbline Advisers trimmed its holdings in Outset Medical, Inc. (NASDAQ:OM) by 67.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 22,418 shares of the company’s stock after selling 46,699 shares during the period. Rhumbline Advisers’ holdings in Outset Medical were worth $86,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Assenagon Asset Management S.A. raised its position in Outset Medical by 60.4% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,515,126 shares of the company’s stock valued at $5,833,000 after purchasing an additional 570,281 shares in the last quarter. Mubadala Investment Co PJSC acquired a new position in shares of Outset Medical in the 4th quarter valued at $7,794,000. PFM Health Sciences LP purchased a new position in shares of Outset Medical in the 4th quarter valued at $5,406,000. Acadian Asset Management LLC raised its stake in Outset Medical by 369.4% during the 1st quarter. Acadian Asset Management LLC now owns 779,242 shares of the company’s stock worth $1,728,000 after acquiring an additional 613,229 shares in the last quarter. Finally, GSA Capital Partners LLP lifted its position in Outset Medical by 5.1% in the first quarter. GSA Capital Partners LLP now owns 540,571 shares of the company’s stock valued at $1,200,000 after acquiring an additional 26,254 shares during the last quarter.

Outset Medical Stock Performance

Shares of NASDAQ OM opened at $0.68 on Tuesday. Outset Medical, Inc. has a 12 month low of $0.44 and a 12 month high of $10.77. The company has a market cap of $35.26 million, a PE ratio of -0.20 and a beta of 1.92. The company has a 50-day simple moving average of $1.34 and a 200-day simple moving average of $2.59. The company has a debt-to-equity ratio of 2.87, a current ratio of 6.80 and a quick ratio of 5.38.

Outset Medical (NASDAQ:OM) last issued its earnings results on Wednesday, August 7th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.07). Outset Medical had a negative return on equity of 143.52% and a negative net margin of 136.72%. The firm had revenue of $27.39 million during the quarter, compared to analysts’ expectations of $31.19 million. During the same period last year, the business posted ($0.90) earnings per share. On average, equities analysts anticipate that Outset Medical, Inc. will post -2.52 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on OM. Royal Bank of Canada lowered shares of Outset Medical from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $6.00 to $3.00 in a research report on Thursday, August 8th. TD Cowen cut their price objective on Outset Medical from $9.00 to $3.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $4.64.

Outset Medical Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.